Results 191 to 200 of about 21,298 (206)

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

Journal of Clinical Oncology, 2018
Patrick Neven, Peter A Fasching, Michelino De Laurentiis   +2 more
exaly  

Fulvestrant/palbociclib

Reactions Weekly, 2022
openaire   +1 more source

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

Cancer Discovery, 2018
Ben O'Leary, Yuan Liu, Fabrice Andre
exaly  

High-dose fulvestrant is a safe and effective therapy for breast cancer

Nature Reviews Clinical Oncology, 2010
Rebecca Kirk
exaly  

Anastrozole and fulvestrant—combination to unlock efficacy

Nature Reviews Clinical Oncology, 2012
Richard Gelber
exaly  

Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer

Cancer Discovery, 2015
Michel van Kruchten, Elisabeth G E De Vries, Martijn van Faassen   +2 more
exaly  

Fulvestrant

2008
openaire   +1 more source

Fulvestrant/palbociclib

Reactions Weekly, 2020
openaire   +2 more sources

Fulvestrant/palbociclib

Reactions Weekly, 2017
openaire   +2 more sources

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Lancet Oncology, The, 2013
Kwok-Leung Cheung, Andrew M Wardley, Anthony Howell   +2 more
exaly